MAMSTR

Across TCGA pan-cancer cohorts, MAMSTR RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of MAMSTR’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MAMSTR RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAMSTR is over-expressed in tumor, although a few such as UCEC and KIRC show the opposite, repressed pattern.

LIHC, UCEC, and LUSC are the cancer types where MAMSTR tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAMSTR RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	II,III,IV	+0.903	<.001	8	view →
UCEC	All	III,IV	−2.414	<.001	6	view →
LUSC	Male	II,III,IV	+1.226	<.001	6	view →
KIRC	Male	II,III,IV	−0.452	<.001	6	view →
CHOL	Male	All	+1.003	<.001	5	view →
COAD	Female	II,III,IV	+0.527	.001	4	view →
LUAD	All	II,III,IV	+0.402	.013	4	view →
THCA	All	All	−0.173	.005	3	view →
BLCA	Male	IV	−1.577	.003	2	view →
PRAD	All	All	−0.747	<.001	2	view →
KIRP	Male	All	−0.290	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

MAMSTR–LIHC

Open the LIHC breakdown →